Breaking News: OmniComm Systems’ TrialMaster SDTM Export Utility Chosen as a Finalist for the 2012 SCDM Data Driven Innovation Award
OmniComm Systems, Inc. (OTCBB:OMCM), one of the fastest growing companies in the Electronic Data Capture marketplace, today announced that its innovative TrialMaster Study Data Tabulation Model (SDTM) Export Utility has been chosen by the Society of Clinical Data Management (SCDM) as a finalist for its 2012 Data Driven Innovation Award. Created in 2007, the Data Driven Innovation Award is presented once a year at the Society for Clinical Data Management’s Annual Meeting to recognize important innovations within the industry that impact the quality or efficiency of clinical data management efforts among clinical trial research.
Created in 2007, the Data Driven Innovation Award is presented once a year at the Society for Clinical Data Management’s Annual Meeting to recognize important innovations within the industry that impact the quality or efficiency of clinical data management efforts among clinical trial research.
The SCDM’s panel of non-partisan Clinical Data Management (CDM) experts reviews each entry to determine the impact on the quality and / or efficiency of a CDM’s work, whether that entry represents an innovative application of a process or technology, and whether that entry represents an active collaboration between a service / technology provider and a study sponsor or between internal teams.
The SDTM Export Utility was specifically designed to interface with OmniComm’s TrialMaster Electronic Data Capture (EDC) suite to automate and facilitate the generation of SDTM datasets for clinical trial analysis and submission.
The SDTM format has gained significant traction in the industry and is the FDA’s preferred format for submission of clinical trial data. The SDTM format consists of a number of standard “domains”, such as demographics and vital signs, each with standard variables of a standard name and data type. Because this structure is always the same, regardless of the therapeutic area and the method and format of data collection, the FDA can review the data with greater efficiency and speed. This in turn leads to shorter approval times.
“Most EDC vendors treat the generation of SDTM datasets as a separate programming exercise at the end of the study, which is needlessly inefficient,” said Keith Howells, SVP of Product Development for OmniComm. “By contrast, TrialMaster allows a study designer to map the source data to the SDTM format using a drag-and-drop mapping tool, which is much more productive and allows reuse across studies. Our customers are generating SDTM datasets within two weeks of study start, giving an enormous head start to the analysis process.”
This marks the 2nd time in the last three years that OmniComm’s technologies have been chosen as a finalist for this coveted award. The winner of the SCDM Data Driven Innovation Award will be chosen by a distinguished group of panelists at the SCDM Annual Conference taking place in Los Angeles, CA September 22nd-25th.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company’s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
What is The StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worthy of our readers attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated StockGuru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. The companies that are discussed in this opinion have not approved the statements made in this release or blog post. This release or blog post contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.